This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) | |
|---|---|
| Name | Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) |
| Native name | Comisión Federal para la Protección contra Riesgos Sanitarios |
| Formed | 2001 |
| Headquarters | Mexico City |
| Parent agency | Secretaría de Salud (México) |
| Jurisdiction | United Mexican States |
| Chief1 name | Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) |
Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) is the federal regulatory authority in Mexico City responsible for health risk protection, licensing, surveillance, and control of products and services related to human health. Established within the framework of the Secretaría de Salud (México), the agency coordinates with state health authorities, international organizations such as the World Health Organization, and regulatory bodies like the Food and Drug Administration and the European Medicines Agency to implement public health standards. COFEPRIS has played a central role in drug registration, medical device oversight, food safety, and tobacco control, influencing policy debates involving the Senate of the Republic (Mexico), the Supreme Court of Justice of the Nation, and civil society organizations.
COFEPRIS was created as part of reforms in the early 2000s under the administration of Vicente Fox to strengthen sanitary regulation and consolidate functions previously distributed across the Secretaría de Salud (México), the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) structure, and state agencies. Its institutional origins relate to earlier bodies such as the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) predecessor units and administrative reforms influenced by practices at the Pan American Health Organization and standards promoted by the World Health Organization. Key legislative frameworks shaping COFEPRIS include reforms enacted by the Congress of the Union (Mexico) and rulings from the Supreme Court of Justice of the Nation that clarified its regulatory remit. Over successive presidencies, including those of Felipe Calderón and Enrique Peña Nieto, COFEPRIS expanded its authority in pharmaceutical regulation and international cooperation, while under Andrés Manuel López Obrador the agency has faced scrutiny over staffing and policy changes.
COFEPRIS is administratively attached to the Secretaría de Salud (México) and organized into directorates and decentralized bodies that align with regulatory domains such as pharmaceuticals, medical devices, food safety, and environmental health. Leadership appointments have often involved officials nominated by the President of Mexico and confirmed through internal procedures involving the Secretaría de Salud (México), with operational oversight linked to ministerial decrees signed by the Secretary of Health (Mexico). Regional coordination occurs with state health secretariats and municipal authorities, and technical advisory committees include experts with affiliations to institutions like the National Autonomous University of Mexico, the Instituto Mexicano del Seguro Social, and the Instituto de Salud para el Bienestar. Administrative units interface with international counterparts including the Food and Drug Administration, the European Medicines Agency, and the Pan American Health Organization for regulatory harmonization.
COFEPRIS’s statutory functions derive from the Federal Health Law and related legal instruments enacted by the Congress of the Union (Mexico) and interpreted by the Supreme Court of Justice of the Nation. Its attributions include licensing and inspection of establishments, registration and control of pharmaceuticals and biologicals, authorization of clinical trials in coordination with ethics committees, and enforcement actions against noncompliant actors such as pharmaceutical companies, importers, and distributors. The agency issues sanitary permits, evaluates marketing authorizations used by multinational corporations and domestic manufacturers linked to firms registered at ports such as Port of Veracruz (Mexico), and coordinates pharmacovigilance with hospitals like the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. COFEPRIS also enforces regulations under treaties to which United Mexican States is party, interacting with entities such as the World Trade Organization when regulatory measures intersect with trade.
COFEPRIS administers registration pathways for medicines and vaccines, inspects manufacturing sites, and oversees post-market surveillance including adverse event reporting systems connected to hospitals and research centers such as the Instituto Nacional de Cancerología. It enforces labeling and composition standards for food products in coordination with the Secretaría de Economía (Mexico) and consumer protection bodies like the Federal Consumer Attorney's Office (PROFECO). In tobacco and alcohol policy, COFEPRIS applies provisions stemming from agreements such as the Framework Convention on Tobacco Control and collaborates with municipal authorities on point-of-sale controls. The agency has implemented risk-based inspection models inspired by practices at the Food and Drug Administration and regulatory convergence efforts with the European Medicines Agency and the Pan American Health Organization.
COFEPRIS participates in national campaigns addressing immunization, food safety alerts, and anti-tobacco initiatives aligned with programs of the Secretaría de Salud (México) and the Instituto Mexicano del Seguro Social. It has issued public advisories during outbreaks involving agents monitored by the World Health Organization and coordinated emergency authorizations for vaccines and therapeutics in collaboration with manufacturers and research institutions including the Instituto Nacional de Cancerología and the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Public communication efforts have involved partnerships with civil society groups and media outlets governed by regulations debated within the Senate of the Republic (Mexico).
COFEPRIS maintains cooperation agreements and memoranda of understanding with international regulatory authorities such as the Food and Drug Administration, the European Medicines Agency, and regional actors facilitated by the Pan American Health Organization. It engages in mutual recognition, information exchange, and capacity-building initiatives with counterparts from countries including Canada, Spain, and Brazil, and participates in multilateral forums under the auspices of the World Health Organization and the World Trade Organization. These arrangements support harmonization of clinical trial standards, joint inspections, and regulatory reliance mechanisms for faster access to medicines.
COFEPRIS has been subject to controversies concerning perceived politicization of appointments, transparency in approval processes for pharmaceuticals, and disputes over regulatory decisions that affected multinational corporations and domestic producers, triggering interventions from the Supreme Court of Justice of the Nation and debates in the Senate of the Republic (Mexico). Critics, including academic groups from the National Autonomous University of Mexico and civil society organizations, have raised concerns about regulatory capacity, conflict-of-interest policies, and responsiveness during public health emergencies. Legal challenges have involved parties invoking provisions of the Federal Law of Administrative Procedure (Mexico) and appeals filed before administrative courts and tribunals. Category:Health in Mexico